NDLI: Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes

Please wait, while we are loading the content...

Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes

Content Provider	Scilit
Author	Sanz-Blasco, Sara Piña-Crespo, Juan Zhang, Xiaofei McKercher, Scott R. Lipton, Stuart A.
Copyright Year	2016
Description	Journal: NeuroReport A recently identified mechanism for oligomeric Aβ-induced glutamate release from astrocytes involves intracellular Ca2+ elevation, potentially by Ca2+-dependent vesicular release. Evidence suggests that levetiracetam (LEV; Keppra), an antiepileptic drug, can improve cognitive performance in both humans with mild cognitive impairment and animal models of Alzheimer disease. Because LEV acts by modulating neurotransmitter release from neurons by interaction with synaptic vesicles, we tested the effect of LEV on Aβ-induced astrocytic release of glutamate. We used a fluorescence resonance energy transfer-based glutamate sensor (termed SuperGluSnFR), whose structure is based on the ligand-binding site of glutamate receptors, to monitor glutamate release from primary cultures of human astrocytes exposed to oligomeric amyloid-β peptide 1–42 (Aβ42). We found that LEV (10 µM) inhibited oligomeric Aβ-induced astrocytic glutamate release. In addition, we show that this Aβ-induced glutamate release from astrocytes is sensitive to tetanus neurotoxin, an inhibitor of the vesicle release machinery. Taken together, our evidence suggests that LEV inhibits Aβ-induced vesicular glutamate release from astrocytes and thus may underlie, at least in part, the ability of LEV to reduce hyperexcitability in Alzheimer disease.
Related Links	http://europepmc.org/articles/pmc4874889?pdf=render https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874889/pdf
Ending Page	709
Page Count	5
Starting Page	705
ISSN	09594965
e-ISSN	1473558X
DOI	10.1097/wnr.0000000000000601
Journal	NeuroReport
Issue Number	9
Volume Number	27
Language	English
Publisher	Ovid Technologies (Wolters Kluwer Health)
Publisher Date	2016-06-15
Access Restriction	Open
Subject Keyword	Journal: NeuroReport Research and Experimental Medicine Alzheimer's Disease, Amyloid-β, Astrocyte, Levetiracetam, Synaptic Vesicle Glycoprotein 2a
Content Type	Text
Resource Type	Article
Subject	Neuroscience

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein

Synaptic Vesicle Glycoprotein 2A: Features and Functions

Positron Emission Computed Tomography Imaging of Synaptic Vesicle Glycoprotein 2A in Alzheimer’s Disease

Differential effects of oligomeric and fibrillar amyloid-β1–42 on astrocyte-mediated inflammation

The synaptic vesicle glycoprotein 2A ligand levetiracetam inhibits presynaptic Ca2+ channels through an intracellular pathway.

Amyloid-β Inhibits Thrombospondin 1 Release From Cultured Astrocytes: Effects on Synaptic Protein Expression

A Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release

Endophilin 1 knockdown prevents synaptic dysfunction induced by oligomeric amyloid β.

The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death

Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes

Similar Documents

Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein

Synaptic Vesicle Glycoprotein 2A: Features and Functions

Positron Emission Computed Tomography Imaging of Synaptic Vesicle Glycoprotein 2A in Alzheimer’s Disease

Differential effects of oligomeric and fibrillar amyloid-β1–42 on astrocyte-mediated inflammation

The synaptic vesicle glycoprotein 2A ligand levetiracetam inhibits presynaptic Ca2+ channels through an intracellular pathway.

Amyloid-β Inhibits Thrombospondin 1 Release From Cultured Astrocytes: Effects on Synaptic Protein Expression

A Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release

Endophilin 1 knockdown prevents synaptic dysfunction induced by oligomeric amyloid β.

The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death

Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes